Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Eribulin, and Veliparib in HRD+ Metastatic Cancer
NCT03032614Phase 2Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Sep 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of veliparib in breast cancer and ovarian cancer, sponsored by UT Health San Antonio. Primary endpoints: Incidence, nature and severity of adverse events and serious adverse events at 1.5 years and Tumor response assessed using RECIST 1.1 guidelines at 1 year. Planned start Sep 2017; status: withdrawn.
02
Drugs
veliparib
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on NCT03032614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03032614.